NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 11 04:00PM ET
8.64
Dollar change
-0.16
Percentage change
-1.82
%
IndexRUT P/E- EPS (ttm)-3.59 Insider Own25.01% Shs Outstand113.63M Perf Week-1.37%
Market Cap1.22B Forward P/E- EPS next Y-3.86 Insider Trans-0.06% Shs Float106.14M Perf Month-41.54%
Enterprise Value568.79M PEG- EPS next Q-0.94 Inst Own67.33% Short Float15.43% Perf Quarter14.44%
Income-367.13M P/S- EPS this Y-16.12% Inst Trans10.51% Short Ratio5.74 Perf Half Y-63.77%
Sales0.00M P/B1.47 EPS next Y1.42% ROA-59.05% Short Interest16.37M Perf YTD-63.33%
Book/sh5.89 P/C1.81 EPS next 5Y-0.41% ROE-64.01% 52W High47.45 -81.79% Perf Year-76.78%
Cash/sh4.79 P/FCF- EPS past 3/5Y-4.75% -59.45% ROIC-53.42% 52W Low6.36 35.85% Perf 3Y4.98%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.62% 7.13% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM9.44% Oper. Margin- ATR (14)0.75 Perf 10Y-
Dividend Ex-Date- Quick Ratio20.35 Sales Y/Y TTM- Profit Margin- RSI (14)33.82 Recom1.35
Dividend Gr. 3/5Y- - Current Ratio20.35 EPS Q/Q-29.58% SMA20-15.41% Beta1.08 Target Price39.68
Payout- Debt/Eq0.03 Sales Q/Q- SMA50-24.56% Rel Volume0.92 Prev Close8.80
Employees191 LT Debt/Eq0.03 EarningsMay 08 BMO SMA200-53.43% Avg Volume2.85M Price8.64
IPOSep 17, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-22.95% - Trades Volume2,628,812 Change-1.82%
Date Action Analyst Rating Change Price Target Change
Jun-24-25Initiated Bernstein Mkt Perform $13
Jun-11-25Resumed Raymond James Outperform $37
Jun-02-25Resumed Oppenheimer Outperform $34
May-29-25Initiated Evercore ISI Outperform $46
Mar-12-25Initiated BMO Capital Markets Outperform $50
Mar-07-25Initiated Scotiabank Sector Outperform $50
Dec-13-24Initiated Robert W. Baird Outperform $46
Nov-26-24Initiated RBC Capital Mkts Outperform $45
Oct-24-24Downgrade JP Morgan Overweight → Neutral $43 → $35
May-21-24Reiterated Chardan Capital Markets Buy $31 → $42
Jul-11-25 11:27AM
Jul-02-25 04:01PM
Jun-30-25 09:45PM
04:05PM
04:01PM
12:46PM Loading…
Jun-24-25 12:46PM
Jun-18-25 09:45AM
Jun-17-25 07:00AM
Jun-16-25 04:05PM
Jun-05-25 07:30AM
May-08-25 07:30AM
Apr-25-25 05:05AM
Apr-24-25 07:30AM
Apr-21-25 04:09PM
Apr-15-25 07:30AM
04:30PM Loading…
Apr-14-25 04:30PM
Apr-01-25 11:50AM
Mar-30-25 03:50AM
Mar-28-25 09:00AM
Mar-20-25 04:30PM
04:19PM
04:10PM
Mar-16-25 07:00PM
Mar-12-25 03:05PM
01:12PM
Mar-11-25 07:30AM
Feb-27-25 07:30AM
Feb-14-25 04:05PM
Feb-13-25 09:35AM
Feb-06-25 09:39AM
07:30AM Loading…
Feb-03-25 07:30AM
Jan-28-25 09:35AM
Jan-21-25 07:30AM
Jan-10-25 06:30AM
Jan-09-25 07:30AM
Jan-08-25 04:05PM
Nov-22-24 06:43AM
Nov-12-24 07:30AM
Nov-07-24 04:15PM
Oct-09-24 07:30AM
Oct-07-24 05:32PM
Sep-23-24 08:56AM
Sep-04-24 09:10AM
08:15AM
Sep-03-24 12:37PM
06:31AM
06:30AM
Aug-29-24 07:30AM
Aug-12-24 10:52PM
05:10PM
Jul-29-24 08:50AM
Jul-18-24 12:00PM
Jul-12-24 08:50AM
Jun-24-24 07:30AM
Jun-13-24 04:40PM
Jun-04-24 06:00AM
May-30-24 07:30AM
May-28-24 07:30AM
May-21-24 08:39PM
12:27PM
07:17AM
May-20-24 05:53PM
04:27PM
04:07PM
04:01PM
11:22AM
09:40AM
09:12AM
08:02AM
07:47AM
07:36AM
06:30AM
May-19-24 08:00AM
May-04-24 05:31AM
May-02-24 11:52PM
04:10PM
Apr-30-24 07:32AM
Mar-27-24 04:05PM
08:30AM
Mar-25-24 12:28PM
07:30AM
Mar-13-24 07:30AM
Mar-07-24 01:19PM
Mar-05-24 10:53AM
07:30AM
Mar-02-24 12:00AM
Feb-29-24 03:02AM
Feb-14-24 04:15PM
Feb-01-24 07:30AM
Jan-26-24 11:01PM
Jan-22-24 10:14PM
Jan-12-24 01:12PM
Jan-11-24 04:05PM
Jan-05-24 09:02AM
07:30AM
Jan-04-24 10:46PM
04:37PM
12:39PM
Jan-03-24 04:25PM
02:46PM
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scalzo Richard WilliamOfficerJun 11 '25Proposed Sale14.751,33019,619Jun 11 04:30 PM
Beskrovnaya OxanaOfficerJun 11 '25Proposed Sale14.752,13231,449Jun 11 04:29 PM
Cox JohnCEO & PresidentJun 05 '25Sale13.354,06054,201142,179Jun 06 04:07 PM
Kerr DouglasChief Medical OfficerJun 05 '25Sale13.351,34217,91692,815Jun 06 04:05 PM
Friedl-Naderer JohannaChief Commercial OfficerJun 05 '25Sale13.351461,94995,911Jun 06 04:03 PM
Kerr DouglasOfficerJun 05 '25Proposed Sale13.351,34217,911Jun 05 04:13 PM
Cox JohnOfficerJun 05 '25Proposed Sale13.354,06054,186Jun 05 04:11 PM
Scalzo Richard WilliamOfficerJun 05 '25Proposed Sale13.3591412,198Jun 05 04:09 PM
Beskrovnaya OxanaOfficerJun 05 '25Proposed Sale13.351,09314,587Jun 05 04:07 PM
Scalzo Richard WilliamOfficerMay 16 '25Proposed Sale11.822,47929,313May 16 04:10 PM
Beskrovnaya OxanaOfficerMay 16 '25Proposed Sale11.822,58930,614May 16 04:09 PM
Friedl-Naderer JohannaChief Commercial OfficerMar 13 '25Sale12.121431,73396,057Mar 13 04:13 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Mar 11 '25Sale11.381,34315,283122,330Mar 13 04:08 PM
Beskrovnaya OxanaChief Scientific OfficerMar 11 '25Sale11.382,15324,501195,840Mar 13 04:08 PM
Beskrovnaya OxanaOfficerMar 11 '25Proposed Sale11.382,15324,493Mar 11 04:09 PM
Scalzo Richard WilliamOfficerMar 11 '25Proposed Sale11.381,34315,278Mar 11 04:08 PM
Kerr DouglasChief Medical OfficerMar 05 '25Sale11.831,34315,88894,157Mar 07 04:08 PM
Cox JohnCEO & PresidentMar 05 '25Sale11.834,06148,042146,239Mar 07 04:07 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Mar 05 '25Sale11.8391710,848123,673Mar 07 04:06 PM
Beskrovnaya OxanaChief Scientific OfficerMar 05 '25Sale11.831,09412,942197,993Mar 07 04:04 PM
Kerr DouglasOfficerMar 05 '25Proposed Sale11.891,34315,968Mar 05 04:10 PM
Cox JohnOfficerMar 05 '25Proposed Sale11.894,06748,356Mar 05 04:09 PM
Beskrovnaya OxanaOfficerMar 05 '25Proposed Sale11.891,09413,007Mar 05 04:08 PM
Scalzo Richard WilliamOfficerMar 05 '25Proposed Sale11.8991510,879Mar 05 04:07 PM
Beskrovnaya OxanaChief Scientific OfficerFeb 18 '25Sale13.952,59836,242199,087Feb 25 05:09 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Feb 18 '25Sale13.952,48834,708124,590Feb 18 05:09 PM
Scalzo Richard WilliamOfficerFeb 18 '25Proposed Sale13.912,48834,608Feb 18 04:15 PM
Beskrovnaya OxanaOfficerFeb 18 '25Proposed Sale13.912,59836,138Feb 18 04:14 PM
Beskrovnaya OxanaChief Scientific OfficerDec 11 '24Sale28.122,33465,632201,685Dec 11 08:41 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Dec 11 '24Sale28.121,45540,915127,078Dec 11 08:40 PM
HIGH SUSANNA GATTIOfficerDec 11 '24Proposed Sale28.335,270149,299Dec 11 04:20 PM
Beskrovnaya OxanaOfficerDec 11 '24Proposed Sale28.332,33466,122Dec 11 04:19 PM
Scalzo Richard WilliamOfficerDec 11 '24Proposed Sale28.331,45541,220Dec 11 04:18 PM
Kersten DirkDirectorDec 06 '24Sale29.34101,6752,983,1445,434,982Dec 10 04:05 PM
Kersten DirkDirectorDec 09 '24Sale29.1834,4371,004,8725,400,545Dec 10 04:05 PM
Kersten DirkDirectorDec 04 '24Sale29.39135,0393,968,7965,540,463Dec 06 04:05 PM
Kersten DirkDirectorDec 05 '24Sale29.053,806110,5645,536,657Dec 06 04:05 PM
Kersten DirkDirectorDec 02 '24Sale29.6781,2012,409,2945,705,234Dec 04 04:05 PM
Kersten DirkDirectorDec 03 '24Sale29.0529,732863,7155,675,502Dec 04 04:05 PM
McNeill JonathanOfficerNov 25 '24Proposed Sale29.6919,987593,414Nov 25 04:11 PM
Forbion Capital Fund IV CooperAffiliateNov 22 '24Proposed Sale30.0062,3011,869,030Nov 22 04:06 PM
Incerti CarloDirectorNov 18 '24Option Exercise8.6916,500143,38516,500Nov 18 07:42 PM
Incerti CarloDirectorNov 18 '24Sale28.7316,500474,0450Nov 18 07:42 PM
Rhodes Jason PDirectorNov 14 '24Sale33.1078225,88415,962Nov 18 05:31 PM
Incerti CarloDirectorNov 18 '24Proposed Sale28.0016,500462,000Nov 18 04:40 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Nov 18 '24Sale28.202,73577,12795,833Nov 18 04:28 PM
Beskrovnaya OxanaChief Scientific OfficerNov 18 '24Sale28.202,85680,539137,519Nov 18 04:28 PM
Farwell WildonOfficerNov 18 '24Proposed Sale28.392,51571,400Nov 18 04:13 PM
Scalzo Richard WilliamOfficerNov 18 '24Proposed Sale28.392,73577,646Nov 18 04:10 PM
Beskrovnaya OxanaOfficerNov 18 '24Proposed Sale28.392,85681,081Nov 18 04:06 PM
McNeill JonathanOfficerNov 18 '24Proposed Sale28.392,65875,460Nov 18 04:05 PM
HIGH SUSANNA GATTIOfficerNov 18 '24Proposed Sale28.392,89282,103Nov 18 04:04 PM
Kersten DirkDirectorNov 13 '24Sale35.2410,803380,69862,301Nov 15 04:05 PM
Kersten DirkDirectorNov 14 '24Sale32.828,929293,0505,786,435Nov 15 04:05 PM
ForDyne B.V.AffiliateNov 14 '24Proposed Sale32.831,500,00049,250,000Nov 14 04:59 PM
Kersten DirkDirectorOct 18 '24Sale35.1613,414471,63673,225Oct 22 04:05 PM
Kersten DirkDirectorOct 21 '24Sale35.061214,24273,104Oct 22 04:05 PM
Kersten DirkDirectorOct 16 '24Sale35.3523,671836,77099,652Oct 18 04:05 PM
Kersten DirkDirectorOct 17 '24Sale35.1713,013457,66786,639Oct 18 04:05 PM
Kersten DirkDirectorOct 02 '24Sale35.3821,518761,307128,764Oct 03 04:05 PM
Kersten DirkDirectorOct 01 '24Sale35.168,423296,153150,282Oct 03 04:05 PM
Kersten DirkDirectorSep 30 '24Sale35.5030,9421,098,577158,705Oct 01 04:05 PM
Kersten DirkDirectorSep 27 '24Sale35.00321,120189,647Oct 01 04:05 PM
Kersten DirkDirectorSep 25 '24Sale35.062,35782,636190,939Sep 27 04:05 PM
Kersten DirkDirectorSep 26 '24Sale35.291,26044,465189,679Sep 27 04:05 PM
Kersten DirkDirectorSep 20 '24Sale36.4579,4112,894,795234,127Sep 24 04:05 PM
Kersten DirkDirectorSep 23 '24Sale35.3240,8311,442,098193,296Sep 24 04:05 PM
Kersten DirkDirectorSep 19 '24Sale36.1778,7392,848,283313,538Sep 20 04:05 PM
Kersten DirkDirectorSep 18 '24Sale35.031,55454,437392,277Sep 20 04:05 PM
HIGH SUSANNA GATTIChief Operating OfficerSep 18 '24Sale34.418,976308,864131,636Sep 19 04:52 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Sep 18 '24Sale34.551,39048,02498,568Sep 19 04:52 PM
Beskrovnaya OxanaChief Scientific OfficerSep 18 '24Sale34.552,33980,812140,375Sep 19 04:51 PM
Scalzo Richard WilliamOfficerSep 18 '24Proposed Sale34.511,39047,964Sep 18 04:24 PM
Beskrovnaya OxanaOfficerSep 18 '24Proposed Sale34.512,33980,715Sep 18 04:23 PM
McNeill JonathanOfficerSep 18 '24Proposed Sale34.511,87064,528Sep 18 04:21 PM
HIGH SUSANNA GATTIOfficerSep 18 '24Proposed Sale34.418,967308,512Sep 18 04:20 PM
Kersten DirkDirectorSep 17 '24Sale35.133,272114,945393,831Sep 18 04:05 PM
Kersten DirkDirectorSep 16 '24Sale35.041,32046,253397,103Sep 18 04:05 PM
Farwell WildonOfficerSep 11 '24Proposed Sale32.432,64585,777Sep 11 04:36 PM
HIGH SUSANNA GATTIOfficerSep 11 '24Proposed Sale32.435,270170,906Sep 11 04:34 PM
Scalzo Richard WilliamOfficerSep 11 '24Proposed Sale32.431,46847,607Sep 11 04:31 PM
Beskrovnaya OxanaOfficerSep 11 '24Proposed Sale32.432,16170,081Sep 11 04:28 PM
McNeill JonathanOfficerSep 11 '24Proposed Sale32.431,82359,120Sep 11 04:26 PM
Beskrovnaya OxanaChief Scientific OfficerSep 11 '24Sale31.892,16168,914142,714Sep 11 04:13 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Sep 11 '24Sale31.891,46846,81599,958Sep 11 04:13 PM
HIGH SUSANNA GATTIChief Operating OfficerSep 11 '24Sale31.895,270168,060140,612Sep 11 04:13 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Sep 06 '24Option Exercise12.56116,4781,463,376227,500Sep 10 04:05 PM
Scalzo Richard WilliamSVP, Head of Finance & Admin.Sep 06 '24Sale32.15126,0744,052,851101,426Sep 10 04:05 PM
Kersten DirkDirectorSep 05 '24Sale35.031,57755,242398,423Sep 09 04:05 PM
Scalzo Richard WilliamOfficerAug 19 '24Proposed Sale33.65126,0734,242,356Sep 06 04:22 PM
McNeill JonathanOfficerSep 05 '24Proposed Sale33.61166,7675,605,442Sep 05 04:34 PM
Cox JohnCEO & PresidentSep 04 '24Buy33.0432,0001,057,2168,000Sep 04 05:42 PM
Kersten DirkDirectorAug 30 '24Sale45.5931,3001,427,063400,000Sep 04 04:05 PM
Kersten DirkDirectorAug 28 '24Sale44.8377,8533,490,029487,708Aug 30 04:05 PM
Kersten DirkDirectorAug 29 '24Sale45.3156,4082,555,754431,300Aug 30 04:05 PM
Kersten DirkDirectorAug 26 '24Sale45.3089,4974,054,408630,964Aug 28 04:05 PM
Kersten DirkDirectorAug 27 '24Sale44.2865,4032,896,045565,561Aug 28 04:05 PM
Kersten DirkDirectorAug 22 '24Sale45.8295,3214,368,083805,549Aug 26 04:05 PM
Kersten DirkDirectorAug 23 '24Sale46.2385,0883,934,005720,461Aug 26 04:05 PM
Kersten DirkDirectorAug 21 '24Sale46.78135,7636,350,605900,870Aug 22 04:05 PM
Last Close
Jul 11 04:00PM ET
0.7341
Dollar change
-0.0098
Percentage change
-1.32
%
XLO Xilio Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-0.84 Insider Own68.53% Shs Outstand51.78M Perf Week5.17%
Market Cap38.01M Forward P/E- EPS next Y-0.80 Insider Trans0.30% Shs Float16.30M Perf Month4.87%
Enterprise Value-43.20M PEG- EPS next Q-0.10 Inst Own16.12% Short Float20.35% Perf Quarter7.96%
Income-54.30M P/S4.10 EPS this Y44.05% Inst Trans-31.00% Short Ratio2.52 Perf Half Y-26.96%
Sales9.27M P/B3.55 EPS next Y-31.76% ROA-58.29% Short Interest3.32M Perf YTD-23.13%
Book/sh0.21 P/C0.43 EPS next 5Y-4.53% ROE-297.84% 52W High1.70 -56.82% Perf Year-24.33%
Cash/sh1.72 P/FCF1.81 EPS past 3/5Y26.76% -11.55% ROIC-313.20% 52W Low0.62 18.40% Perf 3Y-77.13%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin80.74% Volatility3.69% 4.17% Perf 5Y-
Dividend TTM- EV/Sales-4.66 EPS Y/Y TTM67.24% Oper. Margin-614.16% ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.96 Sales Y/Y TTM- Profit Margin-585.54% RSI (14)53.15 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio1.96 EPS Q/Q71.18% SMA206.39% Beta-0.12 Target Price4.00
Payout- Debt/Eq0.73 Sales Q/Q- SMA50-2.76% Rel Volume0.20 Prev Close0.74
Employees64 LT Debt/Eq0.62 EarningsMay 08 BMO SMA200-15.49% Avg Volume1.32M Price0.73
IPOOct 22, 2021 Option/ShortNo / Yes EPS/Sales Surpr.6.59% -34.09% Trades Volume259,123 Change-1.32%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Jul-02-25 04:30PM
Jun-10-25 04:30PM
Jun-05-25 06:38PM
Jun-03-25 04:30PM
Jun-02-25 08:46AM
06:11AM Loading…
06:11AM
May-31-25 08:00AM
May-08-25 07:30AM
May-02-25 04:30PM
Apr-23-25 04:30PM
Apr-04-25 04:30PM
Mar-11-25 08:45AM
07:30AM
Feb-24-25 04:30PM
Feb-13-25 04:17AM
10:44AM Loading…
Feb-12-25 10:44AM
07:35AM
07:33AM
Feb-03-25 04:30PM
Jan-22-25 09:00AM
Jan-21-25 05:05PM
Jan-17-25 04:30PM
Jan-10-25 05:00PM
Dec-19-24 07:30AM
Dec-16-24 07:30AM
Dec-09-24 09:55AM
Dec-03-24 04:30PM
Nov-07-24 09:15AM
09:05AM
Oct-30-24 09:01AM
09:05AM Loading…
Oct-04-24 09:05AM
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shannon James SamuelDirectorJun 16 '25Buy0.6945,00030,87045,000Jun 18 04:57 PM
Shannon James SamuelDirectorJun 17 '25Buy0.6925,00017,21570,000Jun 18 04:57 PM
Russo RenePRESIDENT AND CEOJun 16 '25Buy0.6836,28924,680281,172Jun 18 04:56 PM
Frankenfield Christopher JamesChief Financial OfficerJan 02 '25Sale0.986,9546,84112,421Jan 03 04:15 PM
Brennan Kevin M.SVP, FINANCE AND ACCOUNTINGJan 02 '25Sale0.981,8031,7743,197Jan 03 04:15 PM
GILEAD SCIENCES, INC.10% OwnerDec 18 '24Buy1.041,759,9781,830,3779,105,451Dec 19 04:19 PM
Last Close
Jul 11 04:00PM ET
5.45
Dollar change
0.00
Percentage change
0.00
%
THRD Third Harmonic Bio Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-1.24 Insider Own50.60% Shs Outstand44.96M Perf Week0.37%
Market Cap245.95M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float22.29M Perf Month2.83%
Enterprise Value-22.66M PEG- EPS next Q- Inst Own39.45% Short Float6.64% Perf Quarter55.71%
Income-53.45M P/S- EPS this Y- Inst Trans-43.81% Short Ratio2.73 Perf Half Y-50.27%
Sales0.00M P/B0.90 EPS next Y- ROA-19.42% Short Interest1.48M Perf YTD-47.04%
Book/sh6.06 P/C0.91 EPS next 5Y- ROE-19.94% 52W High16.02 -65.98% Perf Year-54.58%
Cash/sh6.02 P/FCF- EPS past 3/5Y-12.50% -34.70% ROIC-19.45% 52W Low3.18 71.38% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility0.62% 0.85% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-67.34% Oper. Margin- ATR (14)0.05 Perf 10Y-
Dividend Ex-Date- Quick Ratio54.10 Sales Y/Y TTM- Profit Margin- RSI (14)65.60 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio54.10 EPS Q/Q-80.40% SMA200.25% Beta2.13 Target Price4.12
Payout- Debt/Eq0.01 Sales Q/Q- SMA502.94% Rel Volume0.39 Prev Close5.45
Employees53 LT Debt/Eq0.01 EarningsMar 27 BMO SMA200-28.41% Avg Volume541.44K Price5.45
IPOSep 15, 2022 Option/ShortYes / Yes EPS/Sales Surpr.-13.17% - Trades Volume211,207 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-28-25Downgrade Stifel Buy → Hold $23 → $5
Feb-12-25Downgrade Morgan Stanley Overweight → Equal-Weight $20 → $5
Feb-11-25Downgrade Raymond James Outperform → Mkt Perform
Aug-09-24Upgrade Morgan Stanley Equal-Weight → Overweight $12 → $20
Jun-18-24Initiated Stifel Buy $23
Jun-07-24Initiated Raymond James Outperform $18
Dec-16-22Downgrade Jefferies Buy → Hold $30 → $3.60
Dec-15-22Downgrade Morgan Stanley Overweight → Equal-Weight $5
Oct-10-22Initiated Morgan Stanley Overweight $34
Oct-10-22Initiated Jefferies Buy $30
Jun-13-25 06:00AM
Jun-12-25 08:00AM
May-02-25 09:16AM
Apr-14-25 07:55AM
06:45AM
08:10AM Loading…
Mar-27-25 08:10AM
Mar-04-25 09:35AM
Feb-14-25 12:00PM
09:35AM
Feb-12-25 04:41PM
Feb-11-25 07:00AM
06:38AM
Feb-01-25 12:07AM
Nov-25-24 04:00PM
Nov-11-24 09:55AM
04:00PM Loading…
Nov-07-24 04:00PM
08:10AM
Sep-10-24 04:00PM
Aug-26-24 04:00PM
Aug-08-24 08:05AM
May-28-24 04:05PM
May-20-24 04:36PM
May-15-24 12:52PM
08:05AM
May-10-24 07:02PM
Apr-15-24 07:00PM
Mar-28-24 08:30AM
Mar-26-24 09:02PM
01:53PM
08:05AM
04:00PM Loading…
Feb-26-24 04:00PM
Jan-04-24 08:00AM
Dec-29-23 12:00PM
Dec-08-23 01:05PM
Nov-09-23 09:30AM
08:30AM
Oct-31-23 08:30AM
Aug-31-23 08:30AM
Aug-10-23 08:10AM
Jul-26-23 09:40AM
Jul-25-23 08:30AM
Jun-09-23 08:04AM
May-24-23 11:02AM
May-11-23 05:00PM
Mar-29-23 08:05AM
Dec-23-22 06:32AM
Dec-22-22 05:41AM
Dec-15-22 10:10AM
09:53AM
08:49AM
08:22AM
07:00AM
Nov-21-22 04:05PM
Nov-09-22 04:15PM
Nov-02-22 08:01AM
Sep-19-22 04:10PM
Sep-15-22 11:41AM
07:58AM
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Conner Edward R.Chief Medical OfficerNov 08 '24Option Exercise4.202,1178,8912,117Nov 12 05:08 PM
Conner Edward R.Chief Medical OfficerNov 08 '24Sale15.002,11731,7550Nov 12 05:08 PM
BVF PARTNERS L P/ILSee Explanation of ResponsesOct 29 '24Sale14.301,000,00014,300,000176,692Oct 31 05:53 PM
Conner Edward R.Chief Medical OfficerOct 28 '24Option Exercise4.202,67311,2272,673Oct 30 04:17 PM
Conner Edward R.Chief Medical OfficerOct 28 '24Sale15.002,67340,0950Oct 30 04:17 PM
EDWARD CONNEROfficerOct 28 '24Proposed Sale13.154,79062,988Oct 28 04:37 PM
Conner Edward R.Chief Medical OfficerSep 19 '24Option Exercise4.204,79020,1184,790Sep 20 05:36 PM
Conner Edward R.Chief Medical OfficerSep 19 '24Sale15.004,79071,8500Sep 20 05:36 PM
Person JulieCHIEF ADMINISTRATIVE OFFICERSep 18 '24Option Exercise4.205032,113503Sep 20 05:35 PM
Person JulieCHIEF ADMINISTRATIVE OFFICERSep 19 '24Sale14.299,497135,6850Sep 20 05:35 PM
Person JulieCHIEF ADMINISTRATIVE OFFICERSep 18 '24Sale14.005037,0420Sep 20 05:35 PM
EDWARD CONNEROfficerSep 19 '24Proposed Sale13.504,79064,665Sep 19 04:27 PM
JULIE PERSONOfficerSep 18 '24Proposed Sale12.7510,000127,500Sep 18 04:37 PM